Skip to main content
TipRanks
Go Ultimate75% OFF

Torrent Pharmaceuticals Ltd (TORNTPHARM) AI Stock Analysis

8 Followers
IN:TORNTPHARM

Torrent Pharmaceuticals Ltd

(NSE:TORNTPHARM)

Select Model
Rating:62Neutral
Price Target:INR 4,887.00â–²(4.20% Upside)
Action:reiterated
Date:10/23/26

The overall score of 62 reflects a company with strong fundamental business momentum and a positive strategic outlook, as highlighted by robust revenue growth and successful integration progress. However, this is significantly weighed down by poor technical momentum, with the stock in a clear downtrend, and a very expensive valuation (P/E of 70.67) that leaves little room for error. The financial performance is solid but shows some strain on gross margins, making the current price level difficult to justify despite the optimistic long-term narrative from management.

Positive Factors
Revenue and Profitability GrowthSustained revenue growth alongside healthy operating margins indicates broadening earnings capacity across Torrent’s portfolio. The improvement in net margin supports internal funding for launches, field-force investment, and research, while reinforcing resilience over the next several quarters.
Negative Factors
Margin and Cash Conversion PressureGross-margin pressure and weaker cash conversion reduce the quality and predictability of reported earnings, even though profitability remains healthy. If sustained, these trends could constrain reinvestment capacity and make future operating performance more sensitive to product mix and cost conditions.

Torrent Pharmaceuticals Ltd (TORNTPHARM) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%IN:TORNTPHARM+26.85%INDA-5.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.78T
Dividend Yield
0.32%
Average Volume (3M)
23.21K
Price to Earnings (P/E)
76.9
Beta (1Y)
0.43
Revenue Growth
42.06%
EPS Growth
-3.48%
Country
India
Employees
20,341
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Ltd Business Overview & Revenue Model

Company Description

Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key...

How the Company Makes Money

Torrent Pharmaceuticals primarily makes money by selling finished-dose pharmaceutical formulations (branded generics) to healthcare channels (pharmacies, hospitals, and distributors) in India and abroad. In its core India business, revenue is driven...

Torrent Pharmaceuticals Ltd Earnings Call Summary

Earnings Call Date:Oct 23, 2026(Q2-2027)|% Change Since:1.73%|Next Earnings Date:Jan 28, 2027
Earnings Call SentimentPositive

The call was predominantly positive, supported by 51% consolidated revenue growth, 54% operating EBITDA growth, strong Torrent India, Curatio, Brazil, U.S., and semaglutide performance, and integration synergies tracking ahead of plan. The main challenges were JB integration-related disruption, Germany's decline, semaglutide supply-driven share loss, expected U.S. price pressure, and Brazil's approval and competitive environment.

Positive Updates

Strong Consolidated Revenue and EBITDA Growth
Q2 FY27 consolidated revenues were INR 4,979 crores, up 51%, while operating EBITDA was INR 1,666 crores, up 54%. Operating EBITDA margin was 33.5%.

Negative Updates

JB Underlying Revenue Was Flat
The underlying JB business reported revenue of INR 1,086 crores, which was largely flat year-on-year. JB India branded business grew 7% in the quarter, compared with 10% growth in H1.

Company Guidance

Management expects JB India branded business growth in H2 to be higher than double digit and total JB business growth to recover to double digit in H2, with recovery gradually quarter-on-quarter; cost synergies remain at INR 450 crores, with most potentially coming through by the next year and achieved in two years' time instead of three years, while revenue synergies should start gradually coming through next year, with initiatives taking 6-12 months and international opportunities 2-3 years. JB EBITDA margins should continue gradual improvement for the next two, three quarters, while H2 EBITDA margin should be little higher than 33.5%; R&D spend may remain elevated for 2-3 years, with U.S. filings increasing from very low single digits to maybe high single digits and spend expected between 4%-4.5% even in the following year. India field force could potentially expand by 500 MRs or so to something between 9,500-9,600, Brazil should continue to grow double-digit, mid-teens or in that range and at least superior to 10%, closer to 15% growth in the coming years, Germany could see a slight decline in the coming quarters followed by stability after maybe three or four quarters, ROW growth can conservatively be taken at 6%-9%, Brazil semaglutide may launch in the next 6-9 months, Curatio should sustain high growth for at least a couple of years, and generic semaglutide could reach INR 800 crores for the first year and INR 2,000-INR 2,500 in 3-5 years.

Torrent Pharmaceuticals Ltd Financial Statement Overview

Summary

Strong revenue growth (+16.1%) and healthy net margins (15.5%) are offset by a sharp decline in gross margin (48.8% vs. ~75% historically). The balance sheet is conservative (D/E 0.40) with robust ROE (25.8%), though recent asset expansion introduces integration risk. Positive operating cash flow (INR 26.3B) and solid FCF conversion (0.74x) support financial health, but uneven cash flow growth and moderate debt coverage (0.32x) temper the score.

Income Statement

68Positive

Balance Sheet

82Very Positive

Cash Flow

71Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue173.48B139.80B113.17B105.62B94.64B84.19B
Gross Profit88.61B68.24B84.33B77.75B66.36B58.81B
EBITDA56.49B32.57B37.19B35.00B28.81B21.41B
Net Income21.24B21.63B19.11B16.56B12.45B7.77B
Balance Sheet
Total Assets446.15B443.12B149.90B150.61B150.12B131.00B
Cash, Cash Equivalents and Short-Term Investments29.86B23.70B6.91B10.04B7.23B5.83B
Total Debt141.07B150.25B32.02B40.22B53.68B40.70B
Total Liabilities262.42B267.27B73.99B82.04B88.14B71.47B
Stockholders Equity183.73B83.89B75.91B68.56B61.98B59.53B
Cash Flow
Free Cash Flow019.55B19.74B28.33B17.94B16.00B
Operating Cash Flow026.32B25.85B32.66B23.68B18.03B
Investing Cash Flow0-127.49B-5.40B-1.68B-24.15B-1.97B
Financing Cash Flow0105.78B-22.98B-27.80B770.00M-17.81B

Torrent Pharmaceuticals Ltd Technical Analysis

Technical Analysis SentimentNeutral
Last Price4689.95

Price Trends

50DMA4756.82Negative
100DMA4824.29Negative
200DMA4539.14Positive

Market Momentum

MACD-1.81Negative
RSI49.94Neutral
STOCH46.53Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TORNTPHARM, the sentiment is Neutral. The current price of 4689.95 is above the 20-day moving average (MA) of 4634.16, below the 50-day MA of 4756.82, and above the 200-day MA of 4539.14, indicating a neutral trend. The MACD of -1.81 indicates Negative momentum. The RSI at 49.94 is Neutral, neither overbought nor oversold. The STOCH value of 46.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:TORNTPHARM.

Torrent Pharmaceuticals Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:TORNTPHARM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ZYDUSLIFEIN:ZYDUSLIFE70OutperformINR 1.19T28.63―0.08%24.02%-14.86%
IN:LUPININ:LUPIN67NeutralINR 902.01B17.35―0.91%24.22%20.24%
IN:MANKINDIN:MANKIND67NeutralINR 1.08T48.34―0.04%13.27%27.32%
IN:SUNPHARMAIN:SUNPHARMA64NeutralINR 4.48T40.86―0.86%12.13%4.94%
IN:DRREDDYIN:DRREDDY63NeutralINR 1.15T41.01―0.58%-3.60%-52.23%
IN:TORNTPHARMIN:TORNTPHARM62NeutralINR 1.78T76.85―0.32%42.06%-3.48%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

-10%0%10%20%30%IN:TORNTPHARMIN:DRREDDYIN:LUPININ:MANKINDIN:SUNPHARMAIN:ZYDUSLIFEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:TORNTPHARM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:TORNTPHARMTorrent Pharmaceuticals Ltd4689.95930.1024.74%
IN:DRREDDYDr. Reddy's Laboratories Ltd.1380.00144.2911.68%
IN:LUPINLupin Limited1972.50-59.91-2.95%
IN:MANKINDMankind Pharma Ltd.2625.00400.9518.03%
IN:SUNPHARMASun Pharmaceutical Industries Limited1866.95123.187.06%
IN:ZYDUSLIFEZydus Lifesciences Limited1189.00261.5828.21%

Torrent Pharmaceuticals Ltd Corporate Events

Torrent Pharmaceuticals completes electronic dispatch of postal ballot notice

Aug 6, 2026

Torrent Pharmaceuticals Ltd has completed the electronic dispatch of its Postal Ballot Notice to shareholders whose email IDs were registered as of July 31, 2026, in line with the Companies Act, 2013 and SEBI Listing Regulations. The company also pub...

Torrent Pharma Announces Completion of Independent Director’s Term

Aug 1, 2026

Torrent Pharmaceuticals Ltd., a publicly listed Indian pharmaceutical manufacturer and marketer, operates under SEBI’s regulatory framework on both BSE and NSE, serving healthcare markets while maintaining compliance-focused governance structures. It...

Torrent Pharma posts Q1 FY27 earnings call recording online

Jul 30, 2026

Torrent Pharmaceuticals Ltd has uploaded the audio recording of its conference call with analysts and investors discussing financial results for the quarter ended June 30, 2026, to the company’s website, in line with SEBI disclosure regulations. The...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026